Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-005/071
C12N-005/0735
출원번호
US-0998883
(2013-12-18)
등록번호
US-10138465
(2018-11-27)
발명자
/ 주소
Rezania, Alireza
출원인 / 주소
Janssen Biotech, Inc.
대리인 / 주소
Warfield, Mark R.
인용정보
피인용 횟수 :
0인용 특허 :
76
초록
The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both.
대표청구항▼
1. A method for producing pancreatic endocrine cells from human pluripotent stem cells, comprising the steps of: (a) differentiating human pluripotent stem cells into foregut endoderm cells; and(b) differentiating the foregut endoderm cells into pancreatic endocrine cells by treatment with a medium
1. A method for producing pancreatic endocrine cells from human pluripotent stem cells, comprising the steps of: (a) differentiating human pluripotent stem cells into foregut endoderm cells; and(b) differentiating the foregut endoderm cells into pancreatic endocrine cells by treatment with a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor. 2. The method of claim 1, wherein at least ten percent of the pancreatic endocrine cells are positive for NKX6.1, PDX1, and HB9. 3. The method of claim 1, wherein the method enhances the expression of HB9 in NKX6.1 positive pancreatic endoderm precursor cells compared to foregut endoderm cells that are not treated with a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor. 4. The method of claim 1, wherein the method decreases expression of NKX2.2 in pancreatic endocrine cells compared to foregut endoderm cells that are not treated with a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor. 5. The method of claim 1, wherein the method suppresses SOX2 and albumin expression in pancreatic endocrine cells compared to foregut endoderm cells that are not treated with a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor. 6. The method of claim 1, wherein the thyroid hormone is triiodothyronine. 7. The method of claim 1, wherein step (b) comprises culturing in a medium supplemented with triiodothyronine and an ALK5 inhibitor. 8. The method of claim 7, wherein the method enhances HB9 expression in pancreatic endocrine cells when compared to foregut endoderm cells that are not cultured with a medium supplemented with triiodothyronine and an ALK5 inhibitor. 9. The method of claim 1, wherein the medium of step (b) is further supplemented with SANT-1, retinoic acid, and ascorbic acid. 10. The method of claim 1, wherein step (b) comprises formation of pancreatic endocrine cells by culturing pancreatic endocrine precursor cells in a medium supplemented with triiodothyronine. 11. The method of claim 10, wherein the medium is further supplemented with an ALK5 inhibitor. 12. The method of claim 8, wherein said ALK5 inhibitor is selected from the group consisting of ALK5 inhibitor II, ALK5i, SD208, TGF-B inhibitor SB431542, ITD-1, LY2109761, A83-01, LY2157299, TGF-β receptor inh V, TGF-β receptor inh I, TGF-β receptor inh IV, TGF-β receptor inh VII, TGF-β receptor inh VIII, TGF-β receptor inh II, TGF-β receptor inh VI, TGF-β receptor inh III. 13. The method of claim 12, wherein said ALK5 inhibitor is ALK5 inhibitor II. 14. The method of claim 1, wherein said pancreatic endocrine cells produce insulin. 15. The method of claim 1, wherein step (b) comprises differentiating the foregut endoderm cells into pancreatic foregut precursor cells by culturing the foregut endoderm cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 16. The method of claim 1, wherein step (b) comprises differentiating the foregut endoderm cells into pancreatic foregut precursor cells and culturing the pancreatic foregut precursor cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 17. The method of claim 1, wherein step (b) comprises differentiating the foregut endoderm cells into endocrine precursors and further differentiating the endocrine precursor cells into pancreatic endocrine cells by culturing the pancreatic foregut precursor cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 18. The method of claim 1, wherein the method further comprises culturing the pancreatic endocrine cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 19. A method of producing Stage 5 cells comprising culturing human foregut endoderm cells in a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor; wherein said culturing of foregut endoderm cells produces Stage 5 cells. 20. The method of claim 19, wherein at least ten percent of the Stage 5 cells are positive for NKX6.1, PDX1, and HB9. 21. The method of claim 19, wherein the method enhances the expression of HB9 in NKX6.1 Stage 5 cells compared to human foregut endoderm cells that are not cultured in a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor. 22. The method of claim 19, wherein the method decreases expression of NKX2.2 in Stage 5 cells. 23. The method of claim 19, wherein the method suppresses SOX2 and albumin expression in stage 5 cells. 24. The method of claim 19, wherein the thyroid hormone is triiodothyronine. 25. The method of claim 19, wherein the method comprises culturing in a medium supplemented with triiodothyronine and an ALK5 inhibitor. 26. The method of claim 25, wherein the method enhances HB9 expression Stage 5 cells when compared to human foregut endoderm cells that are not cultured with a medium supplemented with triiodothyronine and an ALK5 inhibitor. 27. The method of claim 19, wherein the method further comprises formation of pancreatic endocrine cells by culturing the Stage 5 cells in a medium supplemented with triiodothyronine. 28. The method of claim 27, wherein the medium is further supplemented with an ALK5 inhibitor. 29. The method of claim 19, wherein the medium is further supplemented with a BMP receptor inhibitor and a PKC activator. 30. The method of claim 25, wherein said ALK5 inhibitor is selected from the group consisting of ALK5 inhibitor II, ALK5i, SD208, TGF-B inhibitor SB431542, ITD-1, LY2109761, A83-01, LY2157299, TGF-β receptor inh V, TGF-β receptor inh I, TGF-β receptor inh IV, TGF-β receptor inh VII, TGF-β receptor inh VIII, TGF-β receptor inh II, TGF-β receptor inh VI, TGF-β receptor inh III. 31. The method of claim 30, wherein said ALK5 inhibitor is ALK5 inhibitor II. 32. The method of claim 29, wherein said BMP receptor inhibitor is selected from LDN-193189, Noggin and Chordin, and said PKC activator is selected from TPB, PDBu, PMA and ILV. 33. The method of claim 19, wherein said Stage 5 cells produce insulin. 34. The method of claim 19, wherein the method comprises differentiating the foregut endoderm cells into pancreatic foregut precursor cells by culturing the foregut endoderm cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 35. The method of claim 19, wherein the method comprises differentiating pancreatic foregut precursor cells into the Stage 5 cells by culturing the pancreatic foregut precursor cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 36. The method of claim 19, wherein the method comprises differentiating the Stage 5 cells into pancreatic endocrine cells by culturing the Stage 5 cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 37. A method of (a) increasing HB9 expression and (b) suppressing SOX2 and albumin expression in human pancreatic foregut precursor cells, comprising culturing human pancreatic foregut precursor cells in a medium supplemented with triiodothyronine and an ALK5 inhibitor; wherein said culturing increases HB9 expression and suppresses SOX2 and albumin expression in human pancreatic foregut precursor cells as compared to human pancreatic foregut precursor cells not cultured in a medium supplemented with triiodothyronine and an ALK5 inhibitor. 38. A method of down-regulating glucagon, somatostatin and ghrelin expression in human pancreatic foregut precursor cells, human endocrine precursor cells or human pancreatic endocrine cells, comprising culturing the cells in a medium supplemented with triiodothyronine and an ALK5 inhibitor; wherein said culturing down-regulates glucagon, somatostatin and ghrelin expression in human pancreatic foregut precursor cells, human endocrine precursor cells or human pancreatic endocrine cells as compared to human pancreatic foregut precursor cells, human endocrine precursor cells or human pancreatic endocrine cells not cultured in a medium supplemented with triiodothyronine and an ALK5 inhibitor. 39. The method of claim 38, wherein the medium is further supplemented with SANT-1, retinoic acid, and ascorbic acid. 40. The method of claim 39, wherein the cells are human pancreatic foregut precursor cells, and wherein the medium is further supplemented with FGF7. 41. A method for generating human pancreatic endocrine cells, comprising culturing human foregut endoderm cells in a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor; wherein said culturing of human foregut endoderm cells produces pancreatic endocrine cells. 42. The method of claim 41, wherein the human foregut endoderm cells are cultured in the medium for a period of from about three to about nine days. 43. The method of claim 42, wherein said human foregut endoderm cells are cultured in a first growth medium supplemented with thyroid hormone but not the ALK5 inhibitor for a period of from about two to three days, followed by culturing the resulting cell population in additional growth media supplemented with both thyroid hormone and the ALK5 inhibitor for about three to six days. 44. The method of claim 43, wherein said human foregut endoderm cells are further cultured for a period of about three days in a medium containing said thyroid hormone but not the ALK5 inhibitor. 45. The method of claim 43, wherein said thyroid hormone is triiodothyronine. 46. The method of claim 43, wherein said ALK5 inhibitor is selected from ALK5 inhibitor II, ALK5i, SD208, TGF-B inhibitor SB431542, ITD-1, LY2109761, A83-01, LY2157299, TGF-β receptor inh V, TGF-β receptor inh I, TGF-β receptor inh IV, TGF-β receptor inh VII, TGF-β receptor inh VIII, TGF-β receptor inh II, TGF-β receptor inh VI, TGF-β receptor inh III. 47. The method of claim 41, wherein the human pancreatic endocrine cells express insulin. 48. The method of claim 41, wherein the method comprises one or more of: differentiating foregut endoderm cells into pancreatic foregut precursor cells by culturing the foregut endoderm cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor;culturing pancreatic foregut precursor cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor; ordifferentiating pancreatic endocrine precursor cells into pancreatic endocrine cells by culturing pancreatic endocrine precursor cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 49. The method of claim 41, wherein the method further comprises culturing the pancreatic endocrine cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor. 50. A method for increasing the yield of human β cells via the differentiation of human pluripotent stem cells, comprising culturing said human pluripotent cells in a growth media supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and ALK5 inhibitor; wherein said culturing of human pluripotent stem cells increases the yield of human β cells. 51. The method of claim 50 wherein said thyroid hormone is triiodothyronine. 52. The method of claim 51 wherein said β cells express insulin. 53. The method of claim 50, wherein the method comprises one or more of: differentiating foregut endoderm cells into pancreatic foregut precursor cells by culturing the foregut endoderm cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor;culturing the pancreatic foregut precursor cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor; ordifferentiating pancreatic endocrine precursor cells into pancreatic endocrine cells by culturing pancreatic endocrine precursor cells in a medium supplemented with a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or both thyroid hormone and an ALK5 inhibitor.
Yi, Chin-Feng; Gosiewska, Anna; Roweton, Susan, Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering.
Chatelier Ronald C. (9 Apple Gve Bayswater ; Victoria 3168 AUX) Griesser Hans J. (20 View Road The Patch ; Victoria 3792 AUX) Steele John G. (7 The Carriageway North Rocks ; NSW 2151 AUX) Johnson Gra, Cell growth substrates.
Vyakarnam Murty N. ; Zimmerman Mark C. ; Scopelianos Angelo George ; Chun Iksoo ; Melican Mora C. ; Bazilio Clairene A. ; Roller Mark B. ; Gorky David V., Foam composite for the repair or regeneration of tissue.
Vacanti Joseph P. (Winchester MA) Freeman Michael R. (Boston MA), Genitourinary cell-matrix structure for implantation into a human and a method of making.
Evans Ronald M. (San Diego CA) Rosenfeld Michael G. (San Diego CA) Cerelli Gail (Cardiff CA) Mayo Kelly E. (Wilmette IL) Spiess Joachim (Encinitas CA) Rivier Jean E. F. (La Jolla CA) Vale ; Jr. Wylie, Human inhibin.
McIntosh Kevin R. ; Mosca Joseph D. ; Klyushnenkova Elena N., Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
Bryhan, Marie D.; Gagnon, Paul E.; LaChance, Oliva V.; Shen, Zhong-he; Wang, Hongming, Method for creating a cell growth surface on a polymeric substrate.
Bodnar, Andrea G.; Chiu, Choy-Pik; Gold, Joseph D.; Inokuma, Margaret; Murai, James T.; West, Michael D., Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture.
Dalton, Stephen; Sheppard, Allan; Jones, Karen; Baetge, E. Edward; D'Amour, Kevin A.; Agulnick, Alan D., Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors.
Mason Anthony J. (San Francisco CA) Seeburg Peter H. (Heidelberg DEX), Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic aci.
Mason Anthony J. ; Seeburg Peter H., Nucleic acid encoding the mature .beta..sub.B chain of inhibin and method for synthesizing polypeptides using such nucl.
Mason Anthony J. (San Francisco CA) Seeburg Peter H. (San Francisco CA), Nucleic acid encoding the mature a
상세보기
Mason Anthony J. (San Francisco CA) Seeburg Peter H. (San Francisco CA), Nucleic acid encoding the mature bAchain of inhibin and method for synthesizing.
Vyakarnam Murty N. ; Zimmerman Mark C. ; Scopelianos Angelo George ; Roller Mark B. ; Gorky David V., Porous tissue scaffoldings for the repair of regeneration of tissue.
Murty N. Vyakarnam ; Mark C. Zimmerman ; Angelo George Scopelianos ; Mark B. Roller ; David V. Gorky, Porous tissue scaffoldings for the repair or regeneration of tissue.
Vyakarnam, Murty N.; Zimmerman, Mark C.; Scopelianos, Angelo George; Roller, Mark B.; Gorky, David V., Porous tissue scaffoldings for the repair or regeneration of tissue.
Mistry,Sanjay; Kihm,Anthony J.; Harris,Ian Ross; Harmon,Alexander M.; Messina,Darin J.; Yi,Chin Feng; Gosiewska,Anna, Postpartum cells isolated from umbilical cord tissue, and methods of making and using the same.
MacMichael Donald Bruce Atherton,GBX ; Drake David,GBX ; Arlington Stephen Adrian,GBX ; Normansell Ian David,GBX ; Addicott John Kenneth,GBX ; Divers Moira Sloan,GBX ; Stovold John Spencer,GBX, Process and apparatus for cell sorting.
Melican, Mora Carolynne; Li, Yufu; Brown, Kelly R.; Chun, Iksoo; McAllen, III, John; Rezania, Alireza; Scopelianos, Angelo G.; Vyakarnam, Murty N., Reinforced tissue implants and methods of manufacture and use.
Mistry,Sanjay; Messina,Darin J.; Harris,Ian Ross; Harmon,Alexander M.; Seyda,Agnieszka; Yi,Chin Feng; Gosiewska,Anna, Treatment of retinitis pigmentosa with human umbilical cord cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.